Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.45 |
| ▸ | KDM5A | P29375 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656310 | 0.89 | KDM4E (0.46) | KDM4EMAPTLMNAHPGDHTT | |
| SCHEMBL30656188 | 0.85 | ALDH1A1 (0.47) | KDM4ELMNAALDH1A1ATMKDM5B | |
| SCHEMBL30656076 | 0.84 | ALDH1A1 (0.42) | KDM4EMAPTLMNAALDH1A1ATM | |
| SCHEMBL30656087 | 0.84 | EDNRA (0.48) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30656232 | 0.78 | KDM4E (0.43) | KDM4EMAPTLMNAHPGDHTT | |
| SCHEMBL30656256 | 0.78 | NAAA (0.44) | KDM4EMAPTLMNAHPGDHTT | |
| SCHEMBL30714584 | 0.78 | KDM5B (0.49) | KDM4EMAPTLMNAHPGDHTT | |
| SCHEMBL30656021 | 0.77 | EDNRA (0.53) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30655951 | 0.76 | EDNRA (0.47) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30656086 | 0.76 | ALOX5 (0.55) | KDM4EMAPTLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | claimed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | claimed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | KDM4E 3288/4885MAPT 1361/4885LMNA 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.